title: [Cardiorenal anemia syndrome (review)].
abstract: Cardiorenal anemia syndrome (CRAS) refers to the simultaneous presence of anemia, heart failure (HF), and chronic kidney disease (CKD) that forms a pathologic triad with an observe impact on morbidity and mortality. Certain researches were made regarding the usage of erythropoietin (EPO) in patients with the above mentioned disorders. This leads to the improvement of left ventricular function, quality of life and physical tolerance with decreased risk of hospitalization.  Despite successful anemia treatment with EPO in dialysis patients with CKD, HF and cardiorenal syndrome type 2, it should be important to reveal the target Hb level and role of EPO in this category of patients. According to European guidelines in 85% of hemodialysis patients targeted Hb level should be no more than 11g/dl, moreover, the treatment of anemia can be organized before dialysis and it will certainly increase the quality of life in this type of patients.
authors.affiliation: Yerevan State Medical University after M. Heratsi, Yerevan, Armenia.
authors.forename: A
authors.initials: A
authors.lastname: Minasyan
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D059347:Cardio-Renal Syndrome / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D004921:Erythropoietin / Q000627:therapeutic use; D006333:Heart Failure / Q000503:physiopathology; D006760:Hospitalization; D006801:Humans; D007676:Kidney Failure, Chronic / Q000503:physiopathology; D011788:Quality of Life; D006435:Renal Dialysis; D016896:Treatment Outcome; D016277:Ventricular Function, Left
chemical_list: D004921:Erythropoietin